- Home
- TME vs MDGL Comparison
TME vs MDGL Comparison
Compare TME & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TME | MDGL |
|---|---|---|
| Founded | N/A | 2011 |
| Country | China | United States |
| Employees | 5690 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 12.8B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | TME | MDGL |
|---|---|---|
| Price | $9.51 | $512.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $19.44 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 6.0M | 362.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $10.73 | $58.39 |
| Revenue Next Year | $10.19 | $48.55 |
| P/E Ratio | $15.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.94 | $342.73 |
| 52 Week High | $26.70 | $615.00 |
Technical Indicators
Market Signals| Indicator | TME | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 46.75 |
| Support Level | $8.62 | $503.41 |
| Resistance Level | $9.78 | $555.57 |
| Average True Range (ATR) | 0.27 | 22.73 |
| MACD | 0.05 | -4.73 |
| Stochastic Oscillator | 72.97 | 53.16 |
Price Performance
Historical ComparisonAbout TME Tencent Music Entertainment Group each representing two
Tencent Music is the largest online music streaming platform in China, established in 2016 through the merger of QQ Music, Kuwo Music, and Kugou Music. Tencent, its largest shareholder, holds over 50% of the shares and more than 90% of the voting rights. Beyond streaming services, Tencent Music generates revenue through a diverse range of offerings, including podcasts, livestreaming, concerts, and karaoke.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.